1. Home
  2. ULBI vs SPRO Comparison

ULBI vs SPRO Comparison

Compare ULBI & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ULBI
  • SPRO
  • Stock Information
  • Founded
  • ULBI 1990
  • SPRO 2013
  • Country
  • ULBI United States
  • SPRO United States
  • Employees
  • ULBI N/A
  • SPRO N/A
  • Industry
  • ULBI Industrial Machinery/Components
  • SPRO Biotechnology: Pharmaceutical Preparations
  • Sector
  • ULBI Miscellaneous
  • SPRO Health Care
  • Exchange
  • ULBI Nasdaq
  • SPRO Nasdaq
  • Market Cap
  • ULBI 113.5M
  • SPRO 128.9M
  • IPO Year
  • ULBI 1992
  • SPRO 2017
  • Fundamental
  • Price
  • ULBI $6.70
  • SPRO $2.19
  • Analyst Decision
  • ULBI Strong Buy
  • SPRO Buy
  • Analyst Count
  • ULBI 1
  • SPRO 4
  • Target Price
  • ULBI $14.00
  • SPRO $5.00
  • AVG Volume (30 Days)
  • ULBI 54.1K
  • SPRO 1.1M
  • Earning Date
  • ULBI 11-07-2025
  • SPRO 11-13-2025
  • Dividend Yield
  • ULBI N/A
  • SPRO N/A
  • EPS Growth
  • ULBI N/A
  • SPRO N/A
  • EPS
  • ULBI 0.19
  • SPRO N/A
  • Revenue
  • ULBI $178,853,000.00
  • SPRO $48,576,000.00
  • Revenue This Year
  • ULBI $31.30
  • SPRO N/A
  • Revenue Next Year
  • ULBI $6.24
  • SPRO N/A
  • P/E Ratio
  • ULBI $35.54
  • SPRO N/A
  • Revenue Growth
  • ULBI 5.86
  • SPRO N/A
  • 52 Week Low
  • ULBI $4.07
  • SPRO $0.51
  • 52 Week High
  • ULBI $9.61
  • SPRO $3.22
  • Technical
  • Relative Strength Index (RSI)
  • ULBI 46.65
  • SPRO 50.24
  • Support Level
  • ULBI $6.52
  • SPRO $2.21
  • Resistance Level
  • ULBI $6.85
  • SPRO $2.50
  • Average True Range (ATR)
  • ULBI 0.40
  • SPRO 0.13
  • MACD
  • ULBI -0.01
  • SPRO -0.00
  • Stochastic Oscillator
  • ULBI 27.34
  • SPRO 34.24

About ULBI Ultralife Corporation

Ultralife Corp provides products and services ranging from power solutions to communications and electronics systems to customers across the globe in the government and defense, medical, safety and security, energy, and industrial sectors. The company designs, manufactures, installs, and maintains power and communications systems including rechargeable and non-rechargeable batteries, charging systems, communications and electronics systems and accessories, and custom-engineered systems. The company's segments include Battery and Energy Products, and Communications Systems. It generates maximum revenue from the Battery and Energy Products segment, and from the U.S. The Battery & Energy Products segment includes Lithium 9-volt, cylindrical, and various other non-rechargeable batteries.

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Share on Social Networks: